# XIENCE 28 Global Study

> **NCT03355742** · NA · COMPLETED · sponsor: **Abbott Medical Devices** · enrollment: 963 (actual)

## Conditions studied

- Bleeding Disorder
- Stroke, Ischemic
- Stroke Hemorrhagic
- Hematological Disease
- Thrombocytopenia
- Coagulation Disorder
- Anemia
- Renal Insufficiency
- Coronary Artery Disease

## Interventions

- **DEVICE:** XIENCE
- **DRUG:** DAPT

## Key facts

- **NCT ID:** NCT03355742
- **Lead sponsor:** Abbott Medical Devices
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-09
- **Primary completion:** 2019-10-24
- **Final completion:** 2020-04-30
- **Target enrollment:** 963 (ACTUAL)
- **Last updated:** 2021-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03355742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03355742, "XIENCE 28 Global Study". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03355742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*